A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response ...
Jan 8, 2020
0
15
People with follicular lymphoma, a slow-growing lymphatic-system cancer, who have been treated and are in remission for at least two years, may no longer have what has been considered an incurable disease based on highly ...
Dec 9, 2019
0
3
Cancer deploys a vast array of resources to grow: from instability in its genome to inflammation, as well as the creation of new blood vessels, the microenvironment surrounding the tumour, and the use of mechanisms that allow ...
Aug 21, 2019
0
88
(HealthDay)—Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk, early therapy failure (ETF) follicular lymphoma (FL), prior to the use of rituximab, according to a study published ...
Jul 25, 2019
0
1
Healthy white blood cells, called "T-cells," play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists Zhi Zhang Yang, M.D., and Stephen Ansell, ...
Feb 20, 2019
0
60
The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...
May 1, 2018
0
128
(HealthDay)—Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and autologous T cells that express a CD19-directed CAR (CTL019) are effective for refractory B-cell ...
Dec 11, 2017
0
0
In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) ...
Dec 10, 2017
0
0
An immunology discovery from the laboratories at the University of Southampton has now been shown to improve the outcomes of a common type of blood cancer in patients.
Nov 3, 2017
0
1
(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...
Oct 5, 2017
0
1
